ID: MRFR/Pharma/5373-HCR | 90 Pages | Author: Rahul Gotadki | December 2023
The Tinea corporis market is anticipated to reach USD 18.05 Billion by 2030 at 3.10% CAGR during the forecast period 2022-2030.
Tinea Corporis Market Key players:
Some of the key players in the global tinea corporis market are Taro Pharmaceuticals., Inc., Teva Pharmaceuticals, Inc., Glenmark Pharmaceuticals Inc, Breckenridge Pharmaceutical, Inc., NorthStar Rx LLC, Aurobindo Pharma Limited, and Camber Pharmaceuticals, Inc., AvKare, Inc., Novartis AG, Sebela Pharmaceuticals, Inc., Bayer AG, Blueberry Therapeutics Ltd, Perrigo Company.
Intended Audience
Market Segmentation:
Global tinea corporis market is segmented into drug type, diagnosis, treatment and end-users. Tinea corporis market on basis of drug types is segmented into antifungals, steroids and anti-infective combinations.
Based on diagnosis tinea corporis market is segmented into physical exam, imaging tests. Imaging test is further sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy and others.
Based on treatment tinea corporis market is segmented into antifungal shampoos, antifungal creams, drugs and others. On basis of end-user market is further segmented into hospital pharmacies, drug stores, online pharmacies, dermatology hospitals, medical research centres, academic institutes others.\
Global Tinea Corporis Market by Drug Type
Global Tinea Corporis Market, by Diagnosis
Global Tinea Corporis Market, by Treatment
Global Tinea Corporis Market, by End-Users
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The tinea corporis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of the tinea corporis market.
The European tinea corporis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The tinea corporis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The tinea corporis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Global Tinea Corporis Market Share (%), by Region, 2017
Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon
Regional Market Summary
Geographically, the America holds the highest market share for tinea corporis market and the reason being many market players are engaged in development of new drug product innovation, and as this infection is more prone to humid climatic condition there is an increasing prevalence of fungal infection in this region. Whereas increasing awareness of fungal disease and rising healthcare expenditure by the government are some of the factors responsible for growth of market in this region
Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of fungal infection, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region.
Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of fungal infection, changing lifestyle, increase in population, increasing healthcare expenditure by government are some of the factor responsible for market growth in this region.
Global Tinea Corporis Market, by Region
Report Attribute/Metric | Details |
---|---|
Market Size | 2030 .USD 18.05 Billion |
CAGR | 3.10% (2022-2030) |
Base Year | 2021 |
Forecast Period | 2022-2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Drug Type, Diagnosis, Treatment and End-Users |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Taro Pharmaceuticals., Inc., Teva Pharmaceuticals, Inc., Glenmark Pharmaceuticals Inc, Breckenridge Pharmaceutical, Inc., NorthStar Rx LLC, Aurobindo Pharma Limited, and Camber Pharmaceuticals, Inc., AvKare, Inc., Novartis AG, Sebela Pharmaceuticals, Inc., Bayer AG, Blueberry Therapeutics Ltd, Perrigo Company. |
Key Market Opportunities | Entry of new drug product in market for treatment. |
Key Market Drivers |
|
Key Questions Answered
Why Choose Market Research Future?